OSR Holdings is a NASDAQ-listed healthcare holding company operating through a hub-and-spoke model, where the parent entity funds and seeks to commercialize a portfolio of early-stage healthcare subsidiaries. The company operates primarily in South Korea and Switzerland, with three subsidiaries: Vaximm, Darnatein, and RMC. Vaximm, based in Switzerland, is developing oral T-cell immunotherapies for cancer, with its lead asset VXM01 targeting tumor vasculature rather than tumor cells directly. VXM01 has completed Phase 1 trials in pancreatic cancer and glioblastoma and holds Orphan Drug Designation from both the FDA and EMA for both indications. Darnatein, based in South Korea, is developing injectable synthetic biologics for bone and cartilage regeneration, with a clinical-stage spinal fusion product (DRT-102) and a preclinical osteoarthritis candidate (DRT-101). RMC, also Korea-based, is the only revenue-generating subsidiary — it distributes neurovascular surgical devices, including guide wires, catheters, and embolization coils, to Korean hospitals. RMC lost a key distribution agreement with Penumbra in late 2024 and is seeking replacement mandates. Management plans to transform RMC into a fourth-party logistics platform that consolidates distressed Korean medical device distributors, using OSR Holdings' capital access as a competitive advantage. The pharmaceutical subsidiaries require continuous capital to fund clinical development, with the intended exit being partnerships or acquisitions by larger pharma or device companies.